Author

Diego Herráez‐Aguilar

Universidad Francisco de VitoriaORCID 0000-0002-9764-4210Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Francisco MonroyiD· 2 shared Agustín LahoziD· 1 shared Alberto Mora PerdigueroiD· 1 shared Ana García GarcíaiD· 1 shared Antonio Giráldez Trujillo· 1 shared Carlos del Pozo-RojasiD· 1 shared Clara Luque‐RiojaiD· 1 shared David Calzón LozanoiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

Francisco MonroyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiophysicsThe FASEB JournalPeer-reviewedNov 19, 2025

Metabolic Rigidity as a Mechanical Barrier to Malaria: Flickering Loss in PKLR-Deficient Erythrocytes

Natalia Hernando‐Ospina, Macarena Calero, Guillermo Solís‐Fernández…·Francisco Monroy

This study shows that PKLR-deficient erythrocytes, due to metabolic rigidity, resist Plasmodium yoelii infection by maintaining mechanical properties that hinder parasite-induced membrane changes.

1 citation

mouseimaging

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedFeb 16, 2025

ELOVL6 as a Therapeutic Target: Disrupting c-MYC-Driven Lipid Metabolism to Enhance Chemotherapy in Pancreatic Cancer

Ana García García, María Ferrer Aporta, Germán Vallejo-Palma…·Victor Javier Sanchez-Arevalo Lobo

This study identifies ELOVL6 as a therapeutic target in pancreatic cancer by showing its role in c-MYC-driven lipid metabolism and its impact on chemotherapy efficacy.

21 citationstop 1%

mousehuman

𝕏 PostBluesky